Choreo LLC’s ARK Genomic Revolution ETF ARKG Stock Holding History

Choreo LLC’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-13,501	Closed	-$314K	–	1630
2024 Q2	$314K	Buy	+13,501	New	+$341K	0.01%	1078

Other funds holding ARKG

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

MMEA

Main Management ETF Advisors San Francisco, California $2.68B AUM 24.27% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Choreo LLC's ARKG Position: Q3 2024 in Review

Choreo LLC sold out of ARK Genomic Revolution ETF (ARKG) in Q3 2024, closing a stake of 13,501 shares — an estimated $314K sold.

Choreo LLC first reported a position in ARKG in Q2 2024 and held it in 1 quarter. The position peaked at $314K in Q2 2024. 238 funds tracked by Wall St. Rank hold ARKG as of Q3 2024.

Choreo LLC reported no remaining ARK Genomic Revolution ETF position as of Q3 2024 after selling out during the quarter.
Choreo LLC sold 13,501 ARK Genomic Revolution ETF shares in Q3 2024, an estimated $314K.
Choreo LLC first reported a position in ARK Genomic Revolution ETF in Q2 2024 and held it in 1 quarter.
Choreo LLC's ARK Genomic Revolution ETF position peaked at $314K in Q2 2024.
238 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q3 2024.

Based on Choreo LLC's 13F filing for Q3 2024, filed 7 Nov 2024.